Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Assessing oncologic benefit in clinical trials of immunotherapy agents.

Hales RK, Banchereau J, Ribas A, Tarhini AA, Weber JS, Fox BA, Drake CG.

Ann Oncol. 2010 Oct;21(10):1944-51. doi: 10.1093/annonc/mdq048. Epub 2010 Mar 17. Review.

PMID:
20237004
[PubMed - indexed for MEDLINE]
Free Article
2.

Historic evidence and future directions in clinical trial therapy of solid tumors.

Gollob JA, Bonomi P.

Oncology (Williston Park). 2006 May;20(6 Suppl 5):10-8. Review.

PMID:
16773840
[PubMed - indexed for MEDLINE]
Free Article
3.

A clinical development paradigm for cancer vaccines and related biologics.

Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G; Cancer Vaccine Clinical Trial Working Group.

J Immunother. 2007 Jan;30(1):1-15. Review.

PMID:
17198079
[PubMed - indexed for MEDLINE]
4.

Assessing tumor-related signs and symptoms to support cancer drug approval.

Williams G, Pazdur R, Temple R.

J Biopharm Stat. 2004 Feb;14(1):5-21. Review.

PMID:
15027497
[PubMed - indexed for MEDLINE]
5.

Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.

Adis International Ltd.

Drugs R D. 2003;4(4):243-8.

PMID:
12848590
[PubMed - indexed for MEDLINE]
6.

Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials.

Driscoll JJ, Rixe O.

Cancer J. 2009 Sep-Oct;15(5):401-5. doi: 10.1097/PPO.0b013e3181bdc2e0. Review.

PMID:
19826360
[PubMed - indexed for MEDLINE]
7.

Practice and progress in kidney cancer: methodology for novel drug development.

Rini BI, Weinberg V, Small EJ.

J Urol. 2004 Jun;171(6 Pt 1):2115-21. Review.

PMID:
15126769
[PubMed - indexed for MEDLINE]
8.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
[PubMed - indexed for MEDLINE]
9.

Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.

[No authors listed]

BioDrugs. 2003;17(1):69-72.

PMID:
12534322
[PubMed - indexed for MEDLINE]
10.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.

Health Technol Assess. 2001;5(28):1-110. Review.

PMID:
11701100
[PubMed - indexed for MEDLINE]
Free Article
11.

End points in cancer clinical trials and the drug approval process.

Schilsky RL.

Clin Cancer Res. 2002 Apr;8(4):935-8.

PMID:
11948095
[PubMed - indexed for MEDLINE]
Free Article
12.

Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.

Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology.

Stroke. 2003 Aug;34(8):e109-37. Epub 2003 Jul 17. Erratum in: Stroke. 2003 Nov;34(11):2774.

PMID:
12869717
[PubMed - indexed for MEDLINE]
Free Article
13.

Immunotherapy for advanced renal cell cancer.

Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425. Review.

PMID:
15674877
[PubMed - indexed for MEDLINE]
14.

Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation.

Hillman SL, An MW, O'Connell MJ, Goldberg RM, Schaefer P, Buckner JC, Sargent DJ.

J Clin Oncol. 2009 Jul 1;27(19):3205-10. doi: 10.1200/JCO.2008.18.3269. Epub 2009 May 4.

PMID:
19414682
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
[PubMed - indexed for MEDLINE]
16.

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Lencioni R, Llovet JM.

Semin Liver Dis. 2010 Feb;30(1):52-60. doi: 10.1055/s-0030-1247132. Epub 2010 Feb 19. Review.

PMID:
20175033
[PubMed - indexed for MEDLINE]
17.

Marimastat: BB 2516, TA 2516.

[No authors listed]

Drugs R D. 2003;4(3):198-203. Review.

PMID:
12757409
[PubMed - indexed for MEDLINE]
18.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
[PubMed - indexed for MEDLINE]
19.

Endpoints for assessing drug activity in clinical trials.

Pazdur R.

Oncologist. 2008;13 Suppl 2:19-21. doi: 10.1634/theoncologist.13-S2-19. Review.

PMID:
18434634
[PubMed - indexed for MEDLINE]
Free Article
20.

Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials.

O'Shaughnessy JA, Wittes RE, Burke G, Friedman MA, Johnson JR, Niederhuber JE, Rothenberg ML, Woodcock J, Chabner BA, Temple R.

J Clin Oncol. 1991 Dec;9(12):2225-32.

PMID:
1960563
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk